Value of Radiotherapy in Complex Treatment of Locally Advanced Pancreatic Cancer
https://doi.org/10.37174/2587-7593-2025-8-3-9-17
Abstract
Purpose: To familiarize radiation oncologists and specialists of related specialties with various aspects of a promising, comprehensive approach to patients with locally advanced pancreatic cancer.
Materials and methods: The review includes data from domestic and foreign articles found in PubMed/MEDLINE, as well as a clinical case.
Results: As a clinical example, patients with locally advanced pancreatic cancer who received chemotherapy followed by radiation therapy are presented, and the immediate results of treatment are demonstrated.
Conclusions: Despite the predominant role of chemotherapy and surgery in the treatment of pancreatic cancer, radiation therapy still plays an important role in the comprehensive treatment of this disease as a method that improves local control in resectable, borderline resectable, locally advanced, and recurrent pancreatic cancer. However, there is a lack of data on the methods, target volume determination, and fractionation schemes.
About the Authors
Yu. N. Vinogradova
Russian Scientific Centre of Radiology and Surgical Technologies named after Academician A.M. Granov of the Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
70, Leningradskaya str., Pesochny settlement, St. Petersburg, 197758
Competing Interests:
Not declared.
L. I. Korytova
Russian Scientific Centre of Radiology and Surgical Technologies named after Academician A.M. Granov of the Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
70, Leningradskaya str., Pesochny settlement, St. Petersburg, 197758
Competing Interests:
Not declared.
A. S. Butrimova
Russian Scientific Centre of Radiology and Surgical Technologies named after Academician A.M. Granov of the Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
Butrimova Anastasia Sergeevna
70, Leningradskaya str., Pesochny settlement, St. Petersburg, 197758, +79533244784
Competing Interests:
Not declared.
O. V. Korytov
Russian Scientific Centre of Radiology and Surgical Technologies named after Academician A.M. Granov of the Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
70, Leningradskaya str., Pesochny settlement, St. Petersburg, 197758
Competing Interests:
Not declared.
A. V. Meshechkin
Russian Scientific Centre of Radiology and Surgical Technologies named after Academician A.M. Granov of the Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
70, Leningradskaya str., Pesochny settlement, St. Petersburg, 197758
Competing Interests:
Not declared.
N. V. Ilyin
Russian Scientific Centre of Radiology and Surgical Technologies named after Academician A.M. Granov of the Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
70, Leningradskaya str., Pesochny settlement, St. Petersburg, 197758
Competing Interests:
Not declared.
References
1. Kaprin AD, Starinsky VV, Shakhzadova AO. The State of Cancer Care in Russia in 2023. PA. Herzen Moscow Research Institute of Oncology – Branch of the National Medical Research Radiological Centre of the Russian Ministry of Health. – Moscow, 2024. (In Russ.).
2. International Agency for Research on Cancer WHO Pancreas Source: Globocan 2020. 2020. Available from: http://gcoiarc-fr/today/data/factsheets/cancers/13-Pancreas-fact-sheetpdf.
3. Hidalgo M, Cascinu S, Kleeff J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2015;15(1):8-18. https://doi.org/10.1016/j.pan.2014.10.001 PMID: 25547205.
4. Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22:9694-705. https://doi.org/10.3748/wjg.v22.i44.9694
5. Franko J, Hsu HW, Thirunavukarasu P, et al. Chemotherapy and radiation components of neoadjuvant treatment of pancreatic head adenocarcinoma: Impact on perioperative mortality and long-term survival. Eur J Surg Oncol. 2017;43(2):351-7. https://doi.org/10.1016/j.ejso.2016.10.021
6. Sharabura TM, Bochkareva TN. The Role of Radiation Methods in the Treatment of Pancreatic Cancer. Practical Oncology. 2025;26(1). https://doi.org/10.31917/2601058 (In Russ.).
7. Carrato A, Falcone A, Ducreux M, et al. Systematic review of the burden of pancreatic cancer in europe: Real-world impact on survival, quality of life and costs. J Gastrointest Cancer. 2015; 46:201-11. https://doi.org/10.1007/s12029-015-9724-1.
8. Hammel P, Huguet F, van Laethem JL, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled after 4 months of Gemcitabine with or without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016;315(17):1844-53. https://doi.org/10.1001/jama.2016.4324
9. Fietkau R, Grützmann R, Wittel UA, et al. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial. Strahlenther Onkol. 2021;197(1):8- 18. https://doi.org/10.1007/s00066-020-01680-2
10. Morganti AG, Valentini V, Macchia G, et al. 5-fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: Phase I-II dose-escalation study. Int J Radiat Oncol Biol Phys. 2004;59(5):1454-60. https://doi.org/10.1016/j.ijrobp.2004.01.035
11. Krishnan S, Chadha AS, Suh Y, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation. Int J Radiat Oncol Biol Phys. 2016;94:755-65. https://doi.org/10.1016/j.ijrobp.2015.12.003
12. Herman JM, Chang DT, Goodman KA, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015;121(7):1128-37. https://doi.org/10.1002/cncr.29161
13. Park JJ, Hajj C, Reyngold M, et al. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. Acta Oncol. 2017;56(12):1746-53. https://doi.org/10.1080/0284186X.2017.1342863
14. Balaban EP, Mangu PB, Khorana AA, et al. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(22):2654-68. https://doi.org/10.1200/JCO.2016.67.5561
15. Nazarenko AV, Znatkova YaR, Sagaidak IV, et al. Application of stereotactic radiation therapy for pain relief in patients with unresectable pancreatic cancer. Bulletin of Experimental and Clinical Surgery. 2018;11(3):208-12(In Russ.).
16. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2(7 Suppl 3):S94-S100. https://doi.org/10.1097/JTO.0b013e318074de34
17. Pontoriero A, Iatì G, Cacciola A, et al. Stereotactic Body Radiation Therapy with Simultaneous Integrated Boost in Patients with Spinal Metastases. Technol Cancer Res Treat. 2020;19:1533033820904447. https://doi.org/10.1177/1533033820904447
18. Ferini G, Molino L, Bottalico L, et al. A small case series about safety and effectiveness of a hypofractionated electron beam radiotherapy schedule in five fractions for facial non melanoma skin cancer among frail and elderly patients. Rep Pract Oncol Radiother. 2021;26(1):66-72. https://doi.org/10.5603/RPOR.a2021.0013
19. Reyngold M, O’Reilly EM, Varghese AM, et al. Association of Ablative Radiation Therapy with Survival Among Patients with Inoperable Pancreatic Cancer. JAMA Oncol. 2021;7(5):735-8. https://doi.org/10.1001/jamaoncol.2021.0057
20. Colbert LE, Moningi S, Chadha A, et al. Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC. Adv Radiat Oncol. 2017;2(3):403-15. https://doi.org/10.1016/j.adro.2017.02.004
21. Zhu X, Ju X, Cao Y, et al. Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Target Volume Design. Int J Radiat Oncol Biol Phys. 2019;104(1):101-10. https://doi.org/10.1016/j.ijrobp.2019.01.075
22. Koay EJ, Hanania AN, Hall WA, et al. Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. Pract Radiat Oncol. 2020;10(6):e495-e507. https://doi.org/10.1016/j.prro.2020.01.012
23. Parisi S, Ferini G, Cacciola A, et al. A non-surgical COMBO-therapy approach for locally advanced unresectable pancreatic adenocarcinoma: preliminary results of a prospective study. Radiol Med. 2022;127(2):214-9. https://doi.org/10.1007/s11547-021-01441-w
24. Comito T, Massaro M, Teriaca MA, et al. Can Stereotactic Body Radiation Therapy (SBRT) Improve the Prognosis of Unresectable Locally Advanced Pancreatic Cancer. Long-Term Clinical Outcomes, Toxicity and Prognostic Factors on 142 Patients (STEP Study). Curr Oncol. 2023;30(7):7073-88. https://doi.org/10.3390/curroncol30070513
25. Zhu X, Liu W, Cao Y, et al. Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial. E Clinical Medicine. 2022;55:101764. https://doi.org/10.1016/j.eclinm.2022.101764
26. Fietkau R, Ghadimi M, Grützmann R, et al. Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial. J Clin Oncol. 2022;40:4008. https://doi.org/10.1200/JCO.2022.40.16
27. Strauss VY, Shaw R, Virdee PS, et al. Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2). BMC Cancer. 2019;19:121. https://doi.org/10.1186/s12885-019-5307-z
28. Oar A, Lee M, Le H, et al. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. BMC Cancer. 2021;21:936. https://doi.org/10.1186/s12885-021-08666-y.
29. Portales F, Ychou M, Samalin E, et al. Sequential treatment with gemcitabine/nab-paclitaxel (GA) and FOLFIRINOX (FFX) followed by stereotactic MRI-guided adaptive radiation therapy (SMART) in patients with locally advanced pancreatic cancer (LAPC): GABRINOX-ART phase 2, multicenter trial. J Clin Oncol. 2022;40:TPS4191. https://doi.org/10.1200/JCO.2022.40.16
30. Zhang C, Yang H, Chang C, et al. Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment for patients with metastatic pancreatic adenocarcinoma in China: a multicentre, single-arm, phase II trial (ICSBR) protocol. BMJ Open. 2024;14(7):e084274. https://doi.org/10.1136/bmjopen-2024-084274 PMID: 39013651
Review
For citations:
Vinogradova Yu.N., Korytova L.I., Butrimova A.S., Korytov O.V., Meshechkin A.V., Ilyin N.V. Value of Radiotherapy in Complex Treatment of Locally Advanced Pancreatic Cancer. Journal of oncology: diagnostic radiology and radiotherapy. 2025;8(3):9-17. (In Russ.) https://doi.org/10.37174/2587-7593-2025-8-3-9-17
Views:
21
Email this article 